Context from an existing advisory
Health Canada’s April 9, 2026 public advisory addresses unauthorised injectable peptide drugs sold online. It warns that research-use labelling does not make those products legal or exempt them from regulatory requirements. This is an explanation of that existing notice, not an announcement of a newly issued warning. [1]
For a reader comparing claims, the practical distinction is that a supplier’s description and a regulator’s authorisation are different forms of information. A research label cannot answer every question about what a product is or how it may lawfully be supplied.
A related GLP-1 notice
The January 21, 2026 advisory concerns fake or unauthorised GLP-1 products. It provides context for readers encountering product claims online and directs attention to authorised sources and regulatory status. Its publication date should remain attached whenever the notice is mentioned again. [2]
These notices concern related issues but are not interchangeable. A counterfeit warning is about product authenticity and supply, while a research-use claim raises its own questions. A clear briefing should identify which notice supports a statement rather than combine their headlines into a broader claim.
What to keep with a source
When saving or sharing a regulatory update, keep its issuing authority, date and identification number together. The April peptide notice is RA-81874; the January GLP-1 notice is RA-81518. Linking to the regulator’s current page lets a reader check for later changes. [1, 2]
This coverage does not assess or endorse a particular product. Anglo Peptides publishes this explainer and is also a research-product supplier; that commercial relationship is relevant context for readers. Health decisions belong with a qualified healthcare professional, and regulatory claims should be checked against the applicable official record.